Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation.

ABSTRACT:

Background

Patients with microsatellite stable (MSS) colorectal cancer (CRC) often display resistance to immunotherapy. Epidermal growth factor receptor (EGFR)-targeted therapies have shown potential in enhancing immunotherapy, yet clinical benefits remain unfulfilled, which may relate to inadequate patient stratification.

Methods

Circulating tumor cells and tumor tissues were collected from multicenter cohorts of patients with CRC receiving cetuximab to analyze EGFR variant type III (EGFRvIII) expression and immune infiltration. Syngeneic mouse models of EGFRvIII CRC were used to investigate the combined efficacy of adenosine inhibition and antiprogrammed cell death protein 1 (anti-PD-1).

Results

EGFRvIII mutations are found in about 10% of MSS CRC and are associated

SUBMITTER: Sun F 

PROVIDER: S-EPMC11831272 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature